Figure 3.

Elapegademase and pegademase effects on immune reconstitution in adenosine deaminase–severe combined immune deficiency (ADA–SCID) patients. The number of lymphocyte subpopulations, assessed by flow cytometry at the indicated time [months after initiation of enzyme replacement therapy (ERT)] in a patient receiving elapegademase (ELA–ADA, solid line) and three patients receiving pegademase (ADAGEN, dashed lines). (a) CD19⁺ B cells; (b) CD3⁻16⁺56⁺ natural killer (NK) cells; (c) CD3⁺CD4⁺ T cells; (d) CD3⁺CD8⁺ T cells.